Company Number: 15359894

Analysis Date: 2025-07-20 14:30 UTC

1. Credit Opinion: DECLINE. DOMO PHARMA LIMITED is a newly incorporated micro-entity with minimal financial activity and virtually no operating history (incorporated Dec 2023, first accounts to June 2024). The balance sheet shows only £1 in total net assets, indicating no meaningful capital base or trading results yet. Absence of employees and negligible fixed assets suggests the business is at a very early stage of development. Without financial performance data or cash flow history, there is no evidence of the company’s ability to service debt or meet credit commitments. Extending credit at this stage poses high risk.

2. Financial Strength: The company’s financials are minimal with net assets of only £1 and total assets less current liabilities also £1. There are no reported current assets or liabilities disclosed, and no shareholders’ funds beyond the nominal capital. This extremely limited capital base provides no financial cushion or resilience. The micro-entity classification confirms very small scale. This lack of financial substance signals weak balance sheet strength unsuitable for credit extension.

3. Cash Flow Assessment: No cash flow data is available. The absence of employees and minimal assets implies negligible operating activity and likely no positive working capital. The company has not demonstrated liquidity or cash generation capacity. Without historical cash flows or current asset levels, liquidity risk is high. The bank cannot assess the company’s ability to generate cash to meet short-term obligations.

4. Monitoring Points:

• Monitor future financial statements for signs of revenue generation and profitability.
• Watch for increases in current assets and net current assets indicating improved liquidity.
• Track changes in shareholders’ funds and net assets as an indicator of financial strengthening.
• Observe any credit applications or payment behavior once trading activity commences.
• Review director and company status filings for any significant changes or warnings.